TGFB1 and neoplasm: Though there is extensive research on the involvement of chemokines, cytokines, and their receptors in tumor models [18, 19], our work uniquely identifies molecules specific to anti-PD-L1 and/or anti-TGF-β therapy, suggesting possibilities for combination therapies.